Sildenafil Citrate Tablet, Film Coated
Product Images NDC 51655-794

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Sildenafil Citrate (NDC 51655-794). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northwind Health Company, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Label (51655 794 54 Master Bottle Label Approval Rev A 01 22)

Label (51655 794 54 Master Bottle Label Approval Rev A 01 22)
Label for Sildenafil Tablets USP 100 mg, a film-coated oral tablet. The bottle contains 15 tablets and is labeled as prescription only. Storage instructions specify 20°-25°C with permitted excursions between 15°-30°C. The product is repackaged by Northwind Pharmaceuticals, with additional batch and expiration details shown.*
FDA Label Image

Chemical-structure (Chemical Structure)

Chemical-structure (Chemical Structure)
Chemical structure diagram of sildenafil, the active ingredient in sildenafil citrate tablets. The diagram shows the molecular arrangement with labeled functional groups and bonds.*
FDA Label Image

Figure-1 (Figure 1)

Figure-1 (Figure 1)
Line graph depicting the effect of SILDENAFIL 100 mg versus placebo on systolic blood pressure (in mmHg) over 24 hours following a single oral dose. The x-axis shows time post dose in hours from pre-dose to 24 hours, and the y-axis shows changes in systolic blood pressure. Data points for both SILDENAFIL and placebo are connected by lines for comparison.*
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
A line graph showing the change in systolic blood pressure (SBP) in mmHg over 8 hours postdose. Two lines compare the effects of Doxazosin plus Placebo and Doxazosin plus Sildenafil 25 mg, with SBP changes plotted on the vertical axis and time postdose on the horizontal axis.*
FDA Label Image

Figure-3 (Figure 3)

Figure-3 (Figure 3)
A line graph showing the change in systolic blood pressure (SBP) in mmHg over 8 hours postdose. It compares two treatments: Doxazosin plus Placebo versus Doxazosin plus Sildenafil 50 mg. The x-axis represents time in hours postdose, and the y-axis represents the change in SBP. The graph shows a greater decrease in SBP with Doxazosin plus Sildenafil 50 mg compared to Doxazosin plus Placebo.*
FDA Label Image

Figure-4 (Figure 4)

Figure-4 (Figure 4)
A line graph showing blood pressure changes (mmHg) over 8 hours after dosing. It compares two treatments: Doxazosin with Sildenafil 100 mg versus Doxazosin with placebo, plotting mmHg values against time after dosing, indicating blood pressure decreases and recovery trends for each treatment group.*
FDA Label Image

Figure-5 (Figure 5)

Figure-5 (Figure 5)
A pharmacokinetic curve showing plasma concentrations (ng/ml) of a drug over time post dose (hours), with data points represented by circles connected by a line. The graph depicts plasma levels rising sharply to a peak within 1-2 hours, followed by a gradual decline up to 24 hours. The treatment indicated is a commercial tablet.*
FDA Label Image

Figure-6-1 (Figure 6 1)

Figure-6-1 (Figure 6 1)
A bar chart showing the percentage of patients at endpoint by baseline score for the SILDENAFIL CITRATE 100 mg tablet. The x-axis represents baseline scores from 0 to 5, and the y-axis shows the percentage of patients. Multiple bar groups for each baseline score are differentiated by a legend with categories labeled 0 through 5.*
FDA Label Image

Figure-6-2 (Figure 6 2)

Figure-6-2 (Figure 6 2)
A bar chart showing the percentage of patients at endpoint distributed across different baseline scores from 0 to 5. Each baseline score category contains multiple bars representing subgroups labeled 0 through 5, indicating their respective patient percentage values.*
FDA Label Image

Figure-7 (Figure 7)

Figure-7 (Figure 7)
A bar chart depicting the percentage of patients reporting improvement across different treatments: Placebo (24%, n=463), sildenafil citrate 25 mg (63%, n=214), sildenafil citrate 50 mg (74%, n=391), and sildenafil citrate 100 mg (82%, n=380). The y-axis shows percentage improvement from 0 to 100%. The x-axis shows treatment groups with sample sizes.*
FDA Label Image
Torrent-logo (Torrent Logo)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.